Tests efimosfermin alfa in people with cirrhosis caused by fatty liver disease
Tests efimosfermin alfa against placebo in adults with early cirrhosis from MASH.
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Austin, Baltimore, Chandler, Dallas, Fayetteville, Fresno, Georgetown, Houston, Kansas City, Lancaster, Marietta, Mesa, Miami, New York, Pasadena, Pearland, Rialto, Richmond, San Antonio, Santa Maria, Tucson, Viera, Waco, and Wilson, United StatesSee the 24 sites
- Trial code
- Registry title
- A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 42 people, planned
- Started
- 9 Apr 2025
- Expected to end
- 3 Jul 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Efimosfermin
- Placebo
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with MASH liver disease and compensated cirrhosis (stage F4 fibrosis) confirmed by a liver biopsy.
- Age
- 18 through 75 years
- Sex
- Men and women can join.
- Disease stage
- MASH with compensated cirrhosis, consistent with stage F4 fibrosis, confirmed by liver biopsy.
- Biomarker or test result
- 2 or more of the 5 components of metabolic syndrome, now or in the past.
Main reasons for not taking part
- Chronic liver disease from other causes
- Any history or sign of decompensated liver disease
- History of type 1 diabetes
- ALT or AST at 5 times the upper limit of normal or higher
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Ability to understand and sign a written informed consent form (ICF)
- Age 18 through 75 years at enrollment
- History or presence of 2 or more of the 5 components of metabolic syndrome
- Liver biopsy confirmation of MASH consistent with stage F4 fibrosis
- Other inclusion criteria may apply
Who cannot take part
- Individuals with chronic liver disease from other causes, or any history or evidence of decompensated liver disease
- History of type 1 diabetes
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × the upper limit of normal (ULN)
- Other exclusion criteria may apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Austin, TexasHospital not named in the registryContact: Nomita Kim (principal investigator)Taking people
- Baltimore, MarylandHospital not named in the registryContact: Paul Thuluvath (principal investigator)Taking people
- Chandler, ArizonaHospital not named in the registryContact: Anita Kohli (principal investigator)Taking people
- Dallas, TexasHospital not named in the registryContact: Parvez Mantry (principal investigator)Taking people
- Fayetteville, ArkansasHospital not named in the registryContact: John Poulos (principal investigator)Taking people
- Fresno, CaliforniaHospital not named in the registryContact: Muhammad Sheikh (principal investigator)Taking people
- Georgetown, TexasHospital not named in the registryContact: Nirupama Jerome (principal investigator)Taking people
- Houston, TexasHospital not named in the registryContact: Prasun Jalal (principal investigator)Taking people
- Kansas City, MissouriHospital not named in the registryContact: Bradley Freilich (principal investigator)Taking people
- Lancaster, PennsylvaniaHospital not named in the registryContact: Jatinder Pruthi (principal investigator)Taking people
- Marietta, GeorgiaHospital not named in the registryContact: Aasim Sheikh (principal investigator)Taking people
- Mesa, ArizonaHospital not named in the registryContact: Ann Moore (principal investigator)Taking people
- Miami, FloridaHospital not named in the registryContact: Lazaro M Garcia (principal investigator)Taking people
- New YorkHospital not named in the registryContact: Frances Lee (principal investigator)Taking people
- Pasadena, CaliforniaHospital not named in the registryContact: Edward Mena (principal investigator)Taking people
- Pearland, TexasHospital not named in the registryContact: Jignesh Shah (principal investigator)Taking people
- Rialto, CaliforniaHospital not named in the registryContact: Zeid Kayali (principal investigator)Taking people
- Richmond, VirginiaHospital not named in the registryContact: Michael Fuchs (principal investigator)Taking people
- San Antonio, TexasHospital not named in the registryContact: Eric Lawitz (principal investigator)Taking people
- Santa Maria, CaliforniaHospital not named in the registryContact: Keval Shah (principal investigator)Taking people
- Tucson, ArizonaHospital not named in the registryContact: Aimee Bachelier (principal investigator)Taking people
- Viera, FloridaHospital not named in the registryContact: Rosemary Laird (principal investigator)Taking people
- Waco, TexasHospital not named in the registryContact: Gregg Lucksinger (principal investigator)Taking people
- Wilson, North CarolinaHospital not named in the registryContact: Mitchell Mahmoud (principal investigator)Taking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
The 3 groups in the trial
- Efimosfermin (Dose 1)Treatment being tested
Participants will receive efimosfermin (Dose 1) once every 4 weeks (Q4W).
Treatment: Efimosfermin
- Efimosfermin (Dose 2)Treatment being tested
Participants will receive efimosfermin (Dose 2) Q4W.
Treatment: Efimosfermin
- PlaceboPlacebo, for comparison
Participants will receive placebo Q4W.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Plain-language title
- Tests efimosfermin alfa in people with cirrhosis caused by fatty liver diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06920043, who can take part
- Record updated
- 5 November 2026